Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 9/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.59 |
| ▸ | SYK | P43405 | 4/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.46 |
| ▸ | FCER2 | P06734 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5469781 | 0.81 | PBRM1 (0.51) | NTRK1NTRK3NTRK2LMNAPBRM1 | |
| SCHEMBL5728135 | 0.77 | PDPK1 (1.00) | PDPK1NTRK1SYKCA12CA1 | |
| SCHEMBL31388440 | 0.76 | PDPK1 (0.67) | PDPK1NTRK1SYKCA12CA1 | |
| SCHEMBL5182671 | 0.74 | NTRK1 (1.00) | PDPK1NTRK1SYKCA12CA1 | |
| SCHEMBL5182676 | 0.74 | NTRK1 (1.00) | PDPK1NTRK1SYKCA12CA1 | |
| SCHEMBL5477306 | 0.71 | KDM4E (0.45) | PDPK1NTRK1NTRK3NTRK2PBRM1 | |
| SCHEMBL5813081 | 0.70 | NTRK1 (0.48) | NTRK1SYKNTRK3NTRK2PBRM1 | |
| SCHEMBL5481895 | 0.70 | TDP1 (0.52) | NTRK1NTRK3NTRK2MEN1KMT2A | |
| SCHEMBL5464903 | 0.70 | NTRK1 (0.59) | NTRK1SYKNTRK3NTRK2LMNA | |
| SCHEMBL5728181 | 0.70 | PDPK1 (1.00) | PDPK1NTRK1SYKCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| EP-3590960-B1 | IGG STIMULATED REMYELINATION OF PERIPHERAL NERVES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-03-29 | — | — | EP | disclosed |
| US-20210300997-A1 | IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES | Baxalta GmbH (CH) | 2021-09-30 | — | — | US | disclosed |
| US-20200216518-A1 | IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-09 | — | — | US | disclosed |
| US-10494418-B2 | IgG stimulated remyelination of peripheral nerves | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-12-03 | — | — | US | disclosed |
| EP-2820042-B1 | IGG STIMULATED REMYELINATION OF PERIPHERAL NERVES | Baxalta GmbH (CH) | 2019-07-24 | — | — | EP | disclosed |
| US-20180291087-A1 | IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-11 | — | — | US | disclosed |
| US-9834593-B2 | IgG stimulated remyelination of peripheral nerves | BAXALTA INCORPORATED (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | disclosed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008097249-A2 | METHOD FOR THE TREATMENT OF ANTHRAX TOXICITY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080103107-A1 | Screening Methods | KING'S COLLEGE LONDON (GB) | 2008-05-01 | — | — | US | disclosed |
| WO-2008048466-A2 | BONE RESORPTION DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1794313-A2 | SCREENING METHODS USING C-ABL, FYN AND SYK IN COMBINATION WITH TAU PROTEIN | PROTEOME SCIENCES PLC (GB) | 2007-06-13 | — | — | EP | disclosed |
| US-20070065866-A1 | Compositions and Methods for Suppressing Fibrocytes | WILLIAM MARSH RICE UNIVERSITY | 2007-03-22 | — | — | US | disclosed |
| WO-2005123048-A2 | SCREENING METHODS USING C-ABL, FYN AND SYK IN COMBINATION WITH TAU PROTEIN | PROTEOME SCIENCES PLC (GB) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | PDPK1 369/4885NTRK1 3356/4885SYK 2313/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | PDPK1 369/4885NTRK1 3356/4885SYK 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.